--- title: 'Associate Director, Medical Information and Review at Dyne Therapeutics' canonical: 'https://feeny.ai/job/associate-director-medical-information-and-review-dyne-therapeutics-waltham-ff9hs10jh3sd' type: 'job' last_seen: '2026-10-19' --- # Associate Director, Medical Information and Review at Dyne Therapeutics - **Company:** Dyne Therapeutics - **Location:** Waltham, MA - **Compensation:** $150k–$200k - **Posted:** 2026-09-29 - **Last confirmed live:** 2026-10-19 - **Apply:** https://job-boards.greenhouse.io/dynetherapeutics/jobs/6191800004 ## Job description Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at [https://www.dyne-tx.com/](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DaBhdU0rLyxqDF5MLc_hIfw7usSG4P5AlGZUt689alyH6v7mzOmFdpd9s5X8DlnvZSiEkR5UEisX91xRDuQTa2VgG02ByJmFzR8fXOPz8Zi8%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825271389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=J6tnBKJnocuFhoQSNnLD03mlmX8CCP4Ufz89Tz2BRqY%3D&reserved=0), and follow us on [X](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DLBKooGRVe4UrE2Sa6ReueOswzx2nXn5X8MuiTcNNQ_6lX0cFP8Xf24jpFASx3QmF9Qt-1g3RGsigqX34LIiwMg%3D%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825316922%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=1SaJTlzgJLAz3INco8zVJpHByglVu9H3uR4eaUUwqbY%3D&reserved=0), [LinkedIn](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DV9e03kLdDWSbh0_VwnuvS9iTb21RRXsSKiAaMEbducMXKsrR2S-Gw7FLuap5gHCzvcaUIvGPyAeg1wRzFGrqW9J_Z6Ha8bGtJaWV9voKp-c%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825339609%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bDmOn9uD5vB9%2F2LttEyLg%2BANoH6v3vDFv7SAwVdi%2BoI%3D&reserved=0) and [Facebook](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DCMyzCcuOkxGNqTNEki-upZwJJPBCJLp0a-MvjKwwfPo1XQp8XutL02Vy2Vg3ZmpnCYnPLhHxcgEzFeh-07gg_rWzXbiw64-AClVkXbKyKQs%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825359448%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=exQuTFG7FGBX1V0XPy4zSebLvhQUDksB19Nej8Eg3DQ%3D&reserved=0). Role Summary: The Associate Director, Medical Information and Review plays a critical role in building and executing Dyne’s Medical Information and medical review capabilities as the organization advances toward commercialization and launch readiness. This role serves as a key Medical Affairs partner in the review of promotional and non-promotional materials, ensuring scientific accuracy, medical integrity, fair balance, and alignment with applicable regulatory, legal, compliance, and company standards. The Associate Director also helps develop and maintain high-quality, scientifically balanced Medical Information content, supports inquiry management and vendor oversight, and translates medical inquiry trends, literature, and congress insights into actionable recommendations for internal stakeholders. This role is based in Waltham, MA. Primary Responsibilities Include: - Serve as the core Medical Affairs reviewer within medical and promotional review processes, including Medical, Legal, and Regulatory review committees, ensuring scientific accuracy, integrity, fair balance, and appropriateness of promotional and non-promotional materials - Establish and maintain thorough medical, scientific, clinical, disease-state, and product knowledge to serve as a primary Medical Information subject matter expert on Dyne’s product portfolio, with a focus on neuromuscular diseases and launch readiness priorities - Support Medical Information readiness for product launches and contribute to ongoing support and strategic management across all stages of the product lifecycle by building scalable processes, content libraries, training materials, workflows, and operational best practices - Assist with day-to-day operations, quality oversight, and vendor/contact center activities for Medical Information inquiry handling to provide high-quality service to external stakeholders, including case documentation, escalations, and response quality - Analyze reports, metrics, inquiry trends, literature updates, and congress insights for Medical Information activities and communicate actionable insights to internal stakeholders - Support and participate in congress activities, including execution of pre- and post-congress deliverables, insights gathering, internal readouts, and medical booth representation - Maintain compliance with applicable FDA regulations, industry standards, organizational policies, and Medical Affairs best practices by ensuring all Medical Information and review initiatives are executed with the highest level of integrity - Provide backup and operational support for the development and maintenance of Medical Information response documents addressing unsolicited inquiries from healthcare professionals and other stakeholders - Partner with Regulatory, Legal, Compliance, Commercial, Clinical Development, Scientific Communications, Pharmacovigilance, and other cross-functional stakeholders to support timely, compliant review and approval of materials and advance key organizational initiatives - Operate with Associate Director-level ownership by leading multiple workstreams, facilitating collaboration, improving Medical Information operations, content governance, review processes, systems, SOPs, training, and inspection readiness in a fast-paced, matrixed biotech environment Education and Skills Requirements: - Doctorate degree in a scientific or healthcare discipline required; PharmD, PhD, MD, or equivalent preferred - 8+ years of relevant experience including 5+ in Medical Information, medical review, medical communications, Medical Affairs, or a related function within the pharmaceutical, biotechnology, or healthcare industry - Experience serving as a medical reviewer for promotional and non-promotional materials through Medical, Legal, Regulatory, and/or Promotional Review Committee processes - Strong understanding of FDA regulations, industry guidance, and compliance expectations governing Medical Information, scientific exchange, promotional review, and non-promotional communications - Experience developing, reviewing, and maintaining Medical Information response documents, FAQs, scientific summaries, or related medical/scientific content - Ability to interpret and communicate complex scientific and clinical data clearly, accurately, and appropriately for internal and external audiences - Well versed in medical literature searches, publication review, evidence assessment, and synthesis of scientific information - Experience supporting launch readiness, Medical Information operations, vendor/contact center oversight, congress activities, or inquiry trend analysis preferred - Rare disease, neuromuscular disease, or specialty biopharmaceutical experience preferred - Strong project management, organizational, and process-building skills, with the ability to lead multiple workstreams and improve ways of working - Excellent written, verbal, and interpersonal communication skills, with demonstrated ability to collaborate, influence, and build trusted relationships across functions - High attention to detail, sound judgment, accountability, and commitment to compliance, scientific integrity, and Dyne’s mission and values - Ability to work effectively in a fast-paced, matrixed biotechnology environment with evolving priorities - Willingness to travel up to 25%, including scientific congresses and internal meetings as needed #LI-Onsite MA Pay Range $150,000—$200,000 USD The pay range reflects the base pay range Dyne reasonably expects to pay for this role at the time of posting. Individual compensation depends on factors such as education, experience, job-related knowledge, and demonstrated skills. The statements contained herein reflect general details as necessary to describe the principles functions for this job, the level of knowledge and skill typically required, and the scope of responsibility, but should not be considered an all-inclusive listing of work requirements.  Individuals may perform other duties as assigned, including work in other functional areas to cover absences or relief, to equalize peak work periods or otherwise balance workload. Dyne Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law. ## About Dyne Therapeutics ## Company Overview - **One-liner**: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted nucleic acid therapies for genetically driven neuromuscular diseases using its proprietary FORCE™ platform. - **Entity Type**: Public (NASDAQ: DYN) - **Headquarters**: Waltham, Massachusetts, United States - **Founded**: 2018 - **Founders**: Not publicly available (the company was co-founded by a team of scientists and entrepreneurs; individual names not surfaced in search results) ## Core Business - **Primary industry**: Biotechnology / Biopharmaceuticals – rare neuromuscular disease therapeutics - **Target customers**: B2B / B2G – regulatory agencies, healthcare providers, payers, and most importantly patients with Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease. - **Mission / Purpose**: “Delivering functional improvement for people living with neuromuscular diseases.” [dyne-tx.com](https://www.dyne-tx.com/) ## Products & Services Dyne’s pipeline is built around its FORCE™ platform, which uses an antigen-binding fragment (Fab) conjugated to transferrin receptor 1 (TfR1) to deliver therapeutic payloads to muscle and the central nervous system. - **Z‑rostudirsen (DYNE‑251)** – An investigational therapeutic for DMD patients amenable to exon 51 skipping. Consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to an anti‑TfR1 Fab. Phase 1/2 DELIVER trial met primary endpoint; BLA submission for U.S. Accelerated Approval planned for Q2 2026 with potential launch in Q1 2027. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025) - **Z‑basivarsen (DYNE‑101)** – Investigational therapeutic for DM1, using an antisense oligonucleotide (ASO) conjugated to anti‑TfR1 Fab. Phase 1/2 ACHIEVE trial fully enrolled; Phase 3 HARMONIA trial ongoing. [dyne-tx.com](https://www.dyne-tx.com/pipeline/) - **DYNE‑302** – Preclinical candidate for FSHD, using an siRNA payload to suppress DUX4 expression. [dyne-tx.com](https://www.dyne-tx.com/pipeline/) - **DMD Franchise Expansion** – Four additional development candidates (DYNE‑253, DYNE‑245, DYNE‑244, DYNE‑255) targeting exons 53, 45, 44, and 55 for DMD, entering IND‑enabling studies. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025) ## Market Standing - **Valuation / Market Cap**: Not disclosed in search results (public company; market cap fluctuates with stock price; current figure not provided in the sources). - **Key Metric**: Cash, cash equivalents and marketable securities of **$1.1 billion** as of December 31, 2025, providing runway into Q1 2028. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025) - **Notable Investors / Partners**: Not listed in provided search results (likely institutional investors; prior venture rounds not detailed here). - **Growth Signals**: - Headcount grew **38.2% YoY** to **227 employees** (2025). [linkedin.com](https://www.linkedin.com/company/dynetx) - Positive topline results from DELIVER trial for z‑rostudirsen; potential first product launch in Q1 2027 if approved. - Advancing five distinct clinical/preclinical programs across multiple neuromuscular indications. ## Competitive Advantages - **FORCE™ Platform**: Differentiated delivery technology that uses a TfR1‑binding Fab to enable broad and deep tissue penetration in both muscle and CNS – addressing one of the biggest hurdles in neuromuscular drug development. - **Best‑in‑Class Potential**: Clinical data for z‑rostudirsen showed statistically significant dystrophin expression (5.46% of normal at 6 months, 7‑fold change) and preservation of lung function (FVC%p) compared to placebo, despite a small trial not powered for functional endpoints. - **Broad Pipeline**: Covering multiple exon‑skipping opportunities in DMD as well as entirely different diseases (DM1, FSHD, Pompe) with the same core platform, reducing risk and enabling rapid expansion. ## Strategic Focus - **Regulatory Submission**: File a Biologics License Application (BLA) for z‑rostudirsen in Q2 2026 under U.S. Accelerated Approval pathway. - **Late‑Stage Trials**: Initiate two field‑defining Phase 3 confirmatory trials (FORZETTO for DMD and HARMONIA for DM1) in 2026 following FDA alignment on design. - **Pipeline Expansion**: Move four additional DMD exon‑skipping candidates into IND‑enabling studies and advance preclinical DYNE‑302 (FSHD) toward the clinic. - **Commercial Readiness**: Prepare for potential first‑ever company launch in Q1 2027 with a focus on U.S. market, while also pursuing ex‑U.S. approval pathways. ## Why Work Here - **Mission‑Driven Culture**: The company’s “One Dyne community” ethos emphasizes accountability, transparency, fearlessness, and a relentless drive to deliver functional improvement for patients and families. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/) - **Competitive Benefits**: Medical, dental, vision, 401(k), flexible vacation, paid holidays including a year‑end office closure, short‑ & long‑term disability, HSA/FSA accounts. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/) - **Work Environment**: Office location in Waltham, MA (Boston area). Remote/hybrid policy not specified in search results; likely on‑site or hybrid for lab‑based roles. Career page lists roles such as Associate Director, Oligonucleotide Development; Scientist, RNA; Director of Training – reflecting a mix of research, clinical, and corporate functions. [job-boards.greenhouse.io](https://job-boards.greenhouse.io/dynetherapeutics) - **Growth Opportunity**: Joining a late‑stage biotech with a validated platform, strong cash position, and a clear path to commercialization – offering employees exposure to both R&D and upcoming launch activities. - **Recruitment Scam Warning**: Dyne posts an explicit notice on its careers page that it never requests financial details or payment during hiring; all legitimate emails come from @dyne‑tx.com addresses. ## Sources 1. [dyne-tx.com – Company Overview](https://www.dyne-tx.com/) 2. [dyne-tx.com – Careers & Culture](https://www.dyne-tx.com/careers-culture/) 3. [dyne-tx.com – Pipeline](https://www.dyne-tx.com/pipeline/) 4. [investors.dyne-tx.com – Q4/Full Year 2025 Results](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025) 5. [linkedin.com – Dyne Therapeutics Company Profile](https://www.linkedin.com/company/dynetx) 6. [job-boards.greenhouse.io – Dyne Careers Page](https://job-boards.greenhouse.io/dynetherapeutics) ## Other roles at Dyne Therapeutics - [Director, Government Pricing & Contract Operations](https://feeny.ai/job/director-government-pricing-contract-operations-dyne-therapeutics-waltham-jk69cejw4737) — Waltham, MA - [Senior Director, Medical Affairs Biostatistics](https://feeny.ai/job/senior-director-medical-affairs-biostatistics-dyne-therapeutics-waltham-2f5wq33kjtjp) — Waltham, MA - [Associate Director, Regulatory Operations - Veeva Vault RIM](https://feeny.ai/job/associate-director-regulatory-operations-veeva-vault-rim-dyne-therapeutics-6s40gy5y1631) - [Associate Director, Financial Planning & Analysis (FP&A)](https://feeny.ai/job/associate-director-financial-planning-analysis-fp-a-dyne-therapeutics-waltham-ce1kav783776) — Waltham, MA - [Director, Cost Accounting](https://feeny.ai/job/director-cost-accounting-dyne-therapeutics-waltham-k8qpf11tf80c) — Waltham, MA - [Director, Revenue](https://feeny.ai/job/director-revenue-dyne-therapeutics-waltham-t62v02kw61st) — Waltham, MA - [Associate Director, Market Research & Competitive Intelligence](https://feeny.ai/job/associate-director-market-research-competitive-intelligence-dyne-therapeutics-qc47ze0xw76k) — Waltham, MA - [Senior Director, Financial Planning & Analysis - R&D](https://feeny.ai/job/senior-director-financial-planning-analysis-r-d-dyne-therapeutics-waltham-64shts32jq8w) — Waltham, MA - [Senior Administrative Assistant - US Affiliate](https://feeny.ai/job/senior-administrative-assistant-us-affiliate-dyne-therapeutics-waltham-y3emed522zqq) — Waltham, MA - [Executive Assistant](https://feeny.ai/job/executive-assistant-dyne-therapeutics-waltham-f307nxzh29t2) — Waltham, MA